ANAPTYSBIO INC (ANAB) Stock News
NASDAQ:ANAB - Nasdaq - US0327241065 - Common Stock
ANAB Latest News and Analysis
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Stay updated with the stocks that are on the move in today's pre-market session.
Discover the top movers in Friday's pre-market session and stay informed about market dynamics.
See How AnaptysBio Ranks Among Analysts' Top Picks With Strong Buyback Activity
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative...
Notable Friday Option Activity: IIPR, HUMA, ANAB
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be discontinuedAnticipate...
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
Anaptys Announces Participation in November and December Investor Conferences
Anaptys Announces Participation in November and December Investor Conferences
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative...
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
Top-line Phase 2b data anticipated for ANB032, our BTLA agonist, in atopic dermatitis (AD) in December 2024Top-line Phase 2b data anticipated for...
Anaptys Announces Participation in September Investor Conferences
Anaptys Announces Participation in September Investor Conferences
SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative...
Why AnaptysBio Was Such a Healthy Stock This Week
The company's immediate future looks promising, as it has a drug that should get a clinical readout within months and a deep-pocketed pharmaceutical peer as an investor.
AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering
The company is working on treatments for immunological diseases, including eczema and rheumatoid arthritis.
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi...
ANAB Stock Earnings: AnaptysBio Misses EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips AnaptysBio (NASDAQ:ANAB) just reported results for the second quarter of 2024.A...